CP + CB-MNC

CP + CB-MNC refers to a combination therapy involving chorionic plate-derived cells (CP) and cord blood mononuclear cells (CB-MNC). Both components are types of cell therapies derived from perinatal tissues. - **Chorionic plate-derived cells (CP)** are typically mesenchymal stem/stromal cells isolated from the chorionic plate of the placenta, known for their regenerative and immunomodulatory properties. - **Cord blood mononuclear cells (CB-MNC)** are a heterogeneous population of immune and progenitor cells isolated from human umbilical cord blood, including lymphocytes, monocytes, hematopoietic stem/progenitor cells, and other immune cell types[1][5][6]. The combination is being investigated primarily for its potential in regenerative medicine—particularly in neuroregeneration (e.g., optic nerve injury), wound healing, cerebral palsy, and possibly other neurodevelopmental or degenerative conditions[1][2][5][7]. The mechanism involves modulation of inflammation, promotion of tissue repair/regeneration via paracrine signaling (e.g., secretion of growth factors like GAP-43), reduction in pro-inflammatory cytokines such as TNF-α, upregulation of anti-inflammatory cytokines like IL-10, and support for axonal survival through systemic effects[1][5].